DDR1-IN-11
DDR1-IN-11 (Compound 4) is an inhibitor of Discoidin domain receptor 1 (DDR1) with an IC50 of 46.16 nM. DDR1-IN-11 can achieve an inhibition rate of 99.86% against Z-138 cells at a concentration of 10 μM, and it can be used in the research of acute myeloid leukemia (AML).
연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.
- CAS No.: 639089-54-6
- 화학식: C23H28N8OS
- 분자량:464.59
-
보관:
Please store the product under the recommended conditions in the Certificate of Analysis.
사이즈
가격
재고
수량
Amount: USD 0.00
Please select quantity
or
or
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- 순도&문서
- References
-
Help & FAQs
-
HY-10161
TozasertibAurora A/B/C Inhibitor -
HY-10971
AlisertibAurora A Kinase Inhibitor -
HY-10126
Barasertib-HQPAAurora B Inhibitor -
HY-70044
GSK-1070916Aurora B/C Inhibitor -
HY-10127
BarasertibAurora B Inhibitor -
HY-13252
MK-5108Aurora Kinase Inhibitor -
HY-12054
HesperadinAurora B Inhibitor -
HY-10161R
Tozasertib (Standard)Aurora A/B/C Inhibitor -
HY-50514
AT9283Aurora/JAK Inhibitor -
HY-10179
DanusertibAurora Kinase Inhibitor -
HY-14711
ReversineAutophagy Inducer -
HY-13819
MK-8745Apoptosis Inducer
Biological Activity
제품 설명
DDR1-IN-11 (Compound 4) is an inhibitor of Discoidin domain receptor 1 (DDR1) with an IC50 of 46.16 nM. DDR1-IN-11 can achieve an inhibition rate of 99.86% against Z-138 cells at a concentration of 10 μM, and it can be used in the research of acute myeloid leukemia (AML)[1].
IC50 & Target
|
DDR1 46.16 nM (IC50) |
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| 697 | IC50 |
0.025 μM
Compound: VX-680
|
SANGER: Inhibition of human 697 cell growth in a cell viability assay.
SANGER: Inhibition of human 697 cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| 8-MG-BA | IC50 |
9.328 μM
Compound: VX-680
|
SANGER: Inhibition of human 8-MG-BA cell growth in a cell viability assay.
SANGER: Inhibition of human 8-MG-BA cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| A101D | IC50 |
1.874 μM
Compound: VX-680
|
SANGER: Inhibition of human A101D cell growth in a cell viability assay.
SANGER: Inhibition of human A101D cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| A253 cell line | IC50 |
33.585 μM
Compound: VX-680
|
SANGER: Inhibition of human A253 cell growth in a cell viability assay.
SANGER: Inhibition of human A253 cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| A388 | IC50 |
0.341 μM
Compound: VX-680
|
SANGER: Inhibition of human A388 cell growth in a cell viability assay.
SANGER: Inhibition of human A388 cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| A3-KAW | IC50 |
12.324 μM
Compound: VX-680
|
SANGER: Inhibition of human A3-KAW cell growth in a cell viability assay.
SANGER: Inhibition of human A3-KAW cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| A-431 | IC50 |
0.24 μM
Compound: VX-680
|
Antiproliferative activity against human A431 cells after 48 hrs by CCK8 assay
Antiproliferative activity against human A431 cells after 48 hrs by CCK8 assay
|
[PMID: 29358147] |
| A-431 | IC50 |
0.24 μM
Compound: VX-680, MK-0457
|
Antiproliferative activity against human A431 cells assessed as cell viability after 72 hrs by CCK8 assay
Antiproliferative activity against human A431 cells assessed as cell viability after 72 hrs by CCK8 assay
|
[PMID: 24681066] |
| A498 | IC50 |
135.909 μM
Compound: VX-680
|
SANGER: Inhibition of human A498 cell growth in a cell viability assay.
SANGER: Inhibition of human A498 cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| A4-Fuk | IC50 |
0.116 μM
Compound: VX-680
|
SANGER: Inhibition of human A4-Fuk cell growth in a cell viability assay.
SANGER: Inhibition of human A4-Fuk cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| A549 | GI50 |
35.8 μM
Compound: VX-680
|
Antiproliferative activity against human A549 cells after 48 hrs by MTT assay
Antiproliferative activity against human A549 cells after 48 hrs by MTT assay
|
[PMID: 30502115] |
| A549 | IC50 |
15.06 μM
Compound: VX-680
|
Anticancer activity against human A549 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay
Anticancer activity against human A549 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay
|
[PMID: 35476959] |
| A549 | IC50 |
19.4 μM
Compound: VX-680
|
Cytotoxicity against human A549 cells after 48 hrs by MTT assay
Cytotoxicity against human A549 cells after 48 hrs by MTT assay
|
[PMID: 25812967] |
| A549 | IC50 |
3.05 μM
Compound: VX-680, MK-0457
|
Antiproliferative activity against human A549 cells assessed as cell viability after 72 hrs by CCK8 assay
Antiproliferative activity against human A549 cells assessed as cell viability after 72 hrs by CCK8 assay
|
[PMID: 24681066] |
| A549 | IC50 |
3.9 μM
Compound: VX-680
|
Antiproliferative activity against human A549 cells assessed as reduction in cell viability after 72 hrs by MTT assay
Antiproliferative activity against human A549 cells assessed as reduction in cell viability after 72 hrs by MTT assay
|
[PMID: 31862411] |
| A549 | IC50 |
35.8 μM
Compound: VX-680
|
Antiproliferative activity against human A549 cells after 48 hrs by MTT assay
Antiproliferative activity against human A549 cells after 48 hrs by MTT assay
|
[PMID: 30728112] |
| A549 | IC50 |
6.9 μM
Compound: VX680
|
Antiproliferative activity against human A549 cells incubated for 72 hrs by MTT assay
Antiproliferative activity against human A549 cells incubated for 72 hrs by MTT assay
|
[PMID: 32941989] |
| A704 | IC50 |
33.554 μM
Compound: VX-680
|
SANGER: Inhibition of human A704 cell growth in a cell viability assay.
SANGER: Inhibition of human A704 cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| ACN | IC50 |
2.502 μM
Compound: VX-680
|
SANGER: Inhibition of human ACN cell growth in a cell viability assay.
SANGER: Inhibition of human ACN cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| ALL-PO | IC50 |
0.882 μM
Compound: VX-680
|
SANGER: Inhibition of human ALL-PO cell growth in a cell viability assay.
SANGER: Inhibition of human ALL-PO cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| AM-38 | IC50 |
348.763 μM
Compound: VX-680
|
SANGER: Inhibition of human AM-38 cell growth in a cell viability assay.
SANGER: Inhibition of human AM-38 cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| ARH-77 | IC50 |
61.946 μM
Compound: VX-680
|
SANGER: Inhibition of human ARH-77 cell growth in a cell viability assay.
SANGER: Inhibition of human ARH-77 cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| ATN-1 | IC50 |
2.029 μM
Compound: VX-680
|
SANGER: Inhibition of human ATN-1 cell growth in a cell viability assay.
SANGER: Inhibition of human ATN-1 cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| BaF3 | IC50 |
100 nM
Compound: MK-0457
|
Antiproliferative activity against mouse BaF3 cells harbouring T315I mutant assessed as cell growth inhibition
Antiproliferative activity against mouse BaF3 cells harbouring T315I mutant assessed as cell growth inhibition
|
[PMID: 35551036] |
| BaF3 | IC50 |
30 nM
Compound: VX-680, MK-0457
|
Antiproliferative activity against mouse BA/F3 cells expressing Bcr-Abl T315I mutant
Antiproliferative activity against mouse BA/F3 cells expressing Bcr-Abl T315I mutant
|
[PMID: 20604564] |
| BaF3 | IC50 |
5 μM
Compound: VX-680, MK-0457
|
Inhibition of Bcr-Abl T315I mutant autophosphorylation in mouse BA/F3 cells
Inhibition of Bcr-Abl T315I mutant autophosphorylation in mouse BA/F3 cells
|
[PMID: 20604564] |
| BB30-HNC | IC50 |
0.226 μM
Compound: VX-680
|
SANGER: Inhibition of human BB30-HNC cell growth in a cell viability assay.
SANGER: Inhibition of human BB30-HNC cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| BB49-HNC | IC50 |
88.838 μM
Compound: VX-680
|
SANGER: Inhibition of human BB49-HNC cell growth in a cell viability assay.
SANGER: Inhibition of human BB49-HNC cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| BB65-RCC | IC50 |
1.18 μM
Compound: VX-680
|
SANGER: Inhibition of human BB65-RCC cell growth in a cell viability assay.
SANGER: Inhibition of human BB65-RCC cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| BC1 cell line | IC50 |
42.673 μM
Compound: VX-680
|
SANGER: Inhibition of human BC-1 cell growth in a cell viability assay.
SANGER: Inhibition of human BC-1 cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| BC-3 | IC50 |
570.863 μM
Compound: VX-680
|
SANGER: Inhibition of human BC-3 cell growth in a cell viability assay.
SANGER: Inhibition of human BC-3 cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| BE-13 | IC50 |
0.003 μM
Compound: VX-680
|
SANGER: Inhibition of human BE-13 cell growth in a cell viability assay.
SANGER: Inhibition of human BE-13 cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| Becker | IC50 |
110.994 μM
Compound: VX-680
|
SANGER: Inhibition of human Becker cell growth in a cell viability assay.
SANGER: Inhibition of human Becker cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| BL-41 | IC50 |
0.104 μM
Compound: VX-680
|
SANGER: Inhibition of human BL-41 cell growth in a cell viability assay.
SANGER: Inhibition of human BL-41 cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| BL-70 | IC50 |
0.39 μM
Compound: VX-680
|
SANGER: Inhibition of human BL-70 cell growth in a cell viability assay.
SANGER: Inhibition of human BL-70 cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| BOKU | IC50 |
21.453 μM
Compound: VX-680
|
SANGER: Inhibition of human BOKU cell growth in a cell viability assay.
SANGER: Inhibition of human BOKU cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| BT-474 | IC50 |
245.868 μM
Compound: VX-680
|
SANGER: Inhibition of human BT-474 cell growth in a cell viability assay.
SANGER: Inhibition of human BT-474 cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| BV-173 | IC50 |
0.126 μM
Compound: VX-680
|
SANGER: Inhibition of human BV-173 cell growth in a cell viability assay.
SANGER: Inhibition of human BV-173 cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| C2BBe1 | IC50 |
144.709 μM
Compound: VX-680
|
SANGER: Inhibition of human C2BBe1 cell growth in a cell viability assay.
SANGER: Inhibition of human C2BBe1 cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| C8166 | IC50 |
314.528 μM
Compound: VX-680
|
SANGER: Inhibition of human C8166 cell growth in a cell viability assay.
SANGER: Inhibition of human C8166 cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| CA46 | IC50 |
97.983 μM
Compound: VX-680
|
SANGER: Inhibition of human CA46 cell growth in a cell viability assay.
SANGER: Inhibition of human CA46 cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| CAL-148 | IC50 |
20.993 μM
Compound: VX-680
|
SANGER: Inhibition of human CAL-148 cell growth in a cell viability assay.
SANGER: Inhibition of human CAL-148 cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| Calu-6 | IC50 |
19.239 μM
Compound: VX-680
|
SANGER: Inhibition of human Calu-6 cell growth in a cell viability assay.
SANGER: Inhibition of human Calu-6 cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| CAS-1 | IC50 |
76.477 μM
Compound: VX-680
|
SANGER: Inhibition of human CAS-1 cell growth in a cell viability assay.
SANGER: Inhibition of human CAS-1 cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| CCRF-CEM | IC50 |
0.653 μM
Compound: VX-680
|
SANGER: Inhibition of human CCRF-CEM cell growth in a cell viability assay.
SANGER: Inhibition of human CCRF-CEM cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| CESS | IC50 |
0.313 μM
Compound: VX-680
|
SANGER: Inhibition of human CESS cell growth in a cell viability assay.
SANGER: Inhibition of human CESS cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| CGTH-W-1 | IC50 |
82.761 μM
Compound: VX-680
|
SANGER: Inhibition of human CGTH-W-1 cell growth in a cell viability assay.
SANGER: Inhibition of human CGTH-W-1 cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| CHP-126 | IC50 |
31.198 μM
Compound: VX-680
|
SANGER: Inhibition of human CHP-126 cell growth in a cell viability assay.
SANGER: Inhibition of human CHP-126 cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| CMK | IC50 |
1.421 μM
Compound: VX-680
|
SANGER: Inhibition of human CMK cell growth in a cell viability assay.
SANGER: Inhibition of human CMK cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| COLO 205 | IC50 |
0.019 μM
Compound: 44, MK-0457 (VX-680)
|
Antiproliferative activity against human COLO205 cells by [3H]thymidine uptake assay
Antiproliferative activity against human COLO205 cells by [3H]thymidine uptake assay
|
[PMID: 19447622] |
| COLO-320-HSR | IC50 |
51.416 μM
Compound: VX-680
|
SANGER: Inhibition of human COLO-320-HSR cell growth in a cell viability assay.
SANGER: Inhibition of human COLO-320-HSR cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| COLO-668 | IC50 |
85.995 μM
Compound: VX-680
|
SANGER: Inhibition of human COLO-668 cell growth in a cell viability assay.
SANGER: Inhibition of human COLO-668 cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| COLO-684 | IC50 |
32.644 μM
Compound: VX-680
|
SANGER: Inhibition of human COLO-684 cell growth in a cell viability assay.
SANGER: Inhibition of human COLO-684 cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| COLO-800 | IC50 |
378.381 μM
Compound: VX-680
|
SANGER: Inhibition of human COLO-800 cell growth in a cell viability assay.
SANGER: Inhibition of human COLO-800 cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| COLO-824 | IC50 |
298.069 μM
Compound: VX-680
|
SANGER: Inhibition of human COLO-824 cell growth in a cell viability assay.
SANGER: Inhibition of human COLO-824 cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| COLO-829 | IC50 |
102.049 μM
Compound: VX-680
|
SANGER: Inhibition of human COLO-829 cell growth in a cell viability assay.
SANGER: Inhibition of human COLO-829 cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| COR-L279 | IC50 |
4.759 μM
Compound: VX-680
|
SANGER: Inhibition of human COR-L279 cell growth in a cell viability assay.
SANGER: Inhibition of human COR-L279 cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| COR-L88 | IC50 |
45.278 μM
Compound: VX-680
|
SANGER: Inhibition of human COR-L88 cell growth in a cell viability assay.
SANGER: Inhibition of human COR-L88 cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| CP66-MEL | IC50 |
63.077 μM
Compound: VX-680
|
SANGER: Inhibition of human CP66-MEL cell growth in a cell viability assay.
SANGER: Inhibition of human CP66-MEL cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| CP67-MEL | IC50 |
8.533 μM
Compound: VX-680
|
SANGER: Inhibition of human CP67-MEL cell growth in a cell viability assay.
SANGER: Inhibition of human CP67-MEL cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| CPC-N | IC50 |
61.644 μM
Compound: VX-680
|
SANGER: Inhibition of human CPC-N cell growth in a cell viability assay.
SANGER: Inhibition of human CPC-N cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| CTB-1 | IC50 |
14.033 μM
Compound: VX-680
|
SANGER: Inhibition of human CTB-1 cell growth in a cell viability assay.
SANGER: Inhibition of human CTB-1 cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| CTV-1 | IC50 |
0.588 μM
Compound: VX-680
|
SANGER: Inhibition of human CTV-1 cell growth in a cell viability assay.
SANGER: Inhibition of human CTV-1 cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| CW-2 | IC50 |
545.639 μM
Compound: VX-680
|
SANGER: Inhibition of human CW-2 cell growth in a cell viability assay.
SANGER: Inhibition of human CW-2 cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| D-247MG | IC50 |
84.634 μM
Compound: VX-680
|
SANGER: Inhibition of human D-247MG cell growth in a cell viability assay.
SANGER: Inhibition of human D-247MG cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| D-263MG | IC50 |
157.175 μM
Compound: VX-680
|
SANGER: Inhibition of human D-263MG cell growth in a cell viability assay.
SANGER: Inhibition of human D-263MG cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| D283 Med | IC50 |
256.561 μM
Compound: VX-680
|
SANGER: Inhibition of human D-283MED cell growth in a cell viability assay.
SANGER: Inhibition of human D-283MED cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| D-336MG | IC50 |
118.907 μM
Compound: VX-680
|
SANGER: Inhibition of human D-336MG cell growth in a cell viability assay.
SANGER: Inhibition of human D-336MG cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| D-502MG | IC50 |
186.525 μM
Compound: VX-680
|
SANGER: Inhibition of human D-502MG cell growth in a cell viability assay.
SANGER: Inhibition of human D-502MG cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| Daudi | IC50 |
5.691 μM
Compound: VX-680
|
SANGER: Inhibition of human Daudi cell growth in a cell viability assay.
SANGER: Inhibition of human Daudi cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| DB | IC50 |
332.489 μM
Compound: VX-680
|
SANGER: Inhibition of human DB cell growth in a cell viability assay.
SANGER: Inhibition of human DB cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| DEL | IC50 |
1.256 μM
Compound: VX-680
|
SANGER: Inhibition of human DEL cell growth in a cell viability assay.
SANGER: Inhibition of human DEL cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| DG-75 | IC50 |
45.158 μM
Compound: VX-680
|
SANGER: Inhibition of human DG-75 cell growth in a cell viability assay.
SANGER: Inhibition of human DG-75 cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| DJM-1 | IC50 |
6.347 μM
Compound: VX-680
|
SANGER: Inhibition of human DJM-1 cell growth in a cell viability assay.
SANGER: Inhibition of human DJM-1 cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| DMS-114 | IC50 |
130.131 μM
Compound: VX-680
|
SANGER: Inhibition of human DMS-114 cell growth in a cell viability assay.
SANGER: Inhibition of human DMS-114 cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| DMS-153 | IC50 |
12.043 μM
Compound: VX-680
|
SANGER: Inhibition of human DMS-153 cell growth in a cell viability assay.
SANGER: Inhibition of human DMS-153 cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| DMS-79 | IC50 |
163.774 μM
Compound: VX-680
|
SANGER: Inhibition of human DMS-79 cell growth in a cell viability assay.
SANGER: Inhibition of human DMS-79 cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| DOHH-2 | IC50 |
0.338 μM
Compound: VX-680
|
SANGER: Inhibition of human DOHH-2 cell growth in a cell viability assay.
SANGER: Inhibition of human DOHH-2 cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| DSH1 | IC50 |
65.758 μM
Compound: VX-680
|
SANGER: Inhibition of human DSH1 cell growth in a cell viability assay.
SANGER: Inhibition of human DSH1 cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| DU-145 | IC50 |
0.4 μM
Compound: VX-680, MK-0457
|
Antiproliferative activity against human DU145 cells assessed as cell viability after 72 hrs by CCK8 assay
Antiproliferative activity against human DU145 cells assessed as cell viability after 72 hrs by CCK8 assay
|
[PMID: 24681066] |
| DU-4475 | IC50 |
1.018 μM
Compound: VX-680
|
SANGER: Inhibition of human DU-4475 cell growth in a cell viability assay.
SANGER: Inhibition of human DU-4475 cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| EB2 | IC50 |
446.657 μM
Compound: VX-680
|
SANGER: Inhibition of human EB2 cell growth in a cell viability assay.
SANGER: Inhibition of human EB2 cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| EB-3 | IC50 |
60.256 μM
Compound: VX-680
|
SANGER: Inhibition of human EB-3 cell growth in a cell viability assay.
SANGER: Inhibition of human EB-3 cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| ECC4 | IC50 |
115.642 μM
Compound: VX-680
|
SANGER: Inhibition of human ECC4 cell growth in a cell viability assay.
SANGER: Inhibition of human ECC4 cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| EC-GI-10 | IC50 |
461.596 μM
Compound: VX-680
|
SANGER: Inhibition of human EC-GI-10 cell growth in a cell viability assay.
SANGER: Inhibition of human EC-GI-10 cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| EHEB | IC50 |
419.542 μM
Compound: VX-680
|
SANGER: Inhibition of human EHEB cell growth in a cell viability assay.
SANGER: Inhibition of human EHEB cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| EKVX | IC50 |
199.238 μM
Compound: VX-680
|
SANGER: Inhibition of human EKVX cell growth in a cell viability assay.
SANGER: Inhibition of human EKVX cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| EM-2 | IC50 |
0.266 μM
Compound: VX-680
|
SANGER: Inhibition of human EM-2 cell growth in a cell viability assay.
SANGER: Inhibition of human EM-2 cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| EOL1 | IC50 |
0.335 μM
Compound: VX-680
|
SANGER: Inhibition of human EoL-1-cell cell growth in a cell viability assay.
SANGER: Inhibition of human EoL-1-cell cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| ES1 | IC50 |
3.923 μM
Compound: VX-680
|
SANGER: Inhibition of human ES1 cell growth in a cell viability assay.
SANGER: Inhibition of human ES1 cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| ES3 | IC50 |
36.675 μM
Compound: VX-680
|
SANGER: Inhibition of human ES3 cell growth in a cell viability assay.
SANGER: Inhibition of human ES3 cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| ES4 | IC50 |
0.911 μM
Compound: VX-680
|
SANGER: Inhibition of human ES4 cell growth in a cell viability assay.
SANGER: Inhibition of human ES4 cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| ES5 | IC50 |
209.977 μM
Compound: VX-680
|
SANGER: Inhibition of human ES5 cell growth in a cell viability assay.
SANGER: Inhibition of human ES5 cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| ES6 | IC50 |
16.236 μM
Compound: VX-680
|
SANGER: Inhibition of human ES6 cell growth in a cell viability assay.
SANGER: Inhibition of human ES6 cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| ES7 | IC50 |
154.216 μM
Compound: VX-680
|
SANGER: Inhibition of human ES7 cell growth in a cell viability assay.
SANGER: Inhibition of human ES7 cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| ES8 | IC50 |
0.046 μM
Compound: VX-680
|
SANGER: Inhibition of human ES8 cell growth in a cell viability assay.
SANGER: Inhibition of human ES8 cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| ETK-1 | IC50 |
1.136 μM
Compound: VX-680
|
SANGER: Inhibition of human ETK-1 cell growth in a cell viability assay.
SANGER: Inhibition of human ETK-1 cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| EVSA-T | IC50 |
21.15 μM
Compound: VX-680
|
SANGER: Inhibition of human EVSA-T cell growth in a cell viability assay.
SANGER: Inhibition of human EVSA-T cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| EW-1 | IC50 |
1.186 μM
Compound: VX-680
|
SANGER: Inhibition of human EW-1 cell growth in a cell viability assay.
SANGER: Inhibition of human EW-1 cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| EW-11 | IC50 |
307.692 μM
Compound: VX-680
|
SANGER: Inhibition of human EW-11 cell growth in a cell viability assay.
SANGER: Inhibition of human EW-11 cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| EW-12 | IC50 |
622.142 μM
Compound: VX-680
|
SANGER: Inhibition of human EW-12 cell growth in a cell viability assay.
SANGER: Inhibition of human EW-12 cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| EW-13 | IC50 |
54.265 μM
Compound: VX-680
|
SANGER: Inhibition of human EW-13 cell growth in a cell viability assay.
SANGER: Inhibition of human EW-13 cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| EW-16 | IC50 |
0.238 μM
Compound: VX-680
|
SANGER: Inhibition of human EW-16 cell growth in a cell viability assay.
SANGER: Inhibition of human EW-16 cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| EW-18 | IC50 |
640.681 μM
Compound: VX-680
|
SANGER: Inhibition of human EW-18 cell growth in a cell viability assay.
SANGER: Inhibition of human EW-18 cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| EW-24 | IC50 |
148.893 μM
Compound: VX-680
|
SANGER: Inhibition of human EW-24 cell growth in a cell viability assay.
SANGER: Inhibition of human EW-24 cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| EW-3 | IC50 |
13.74 μM
Compound: VX-680
|
SANGER: Inhibition of human EW-3 cell growth in a cell viability assay.
SANGER: Inhibition of human EW-3 cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| GAK | IC50 |
77.801 μM
Compound: VX-680
|
SANGER: Inhibition of human GAK cell growth in a cell viability assay.
SANGER: Inhibition of human GAK cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| GB-1 | IC50 |
2.016 μM
Compound: VX-680
|
SANGER: Inhibition of human GB-1 cell growth in a cell viability assay.
SANGER: Inhibition of human GB-1 cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| GCIY | IC50 |
8.37 μM
Compound: VX-680
|
SANGER: Inhibition of human GCIY cell growth in a cell viability assay.
SANGER: Inhibition of human GCIY cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| GDM-1 | IC50 |
38.912 μM
Compound: VX-680
|
SANGER: Inhibition of human GDM-1 cell growth in a cell viability assay.
SANGER: Inhibition of human GDM-1 cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| GI-1 | IC50 |
42.919 μM
Compound: VX-680
|
SANGER: Inhibition of human GI-1 cell growth in a cell viability assay.
SANGER: Inhibition of human GI-1 cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| GI-ME-N | IC50 |
19.823 μM
Compound: VX-680
|
SANGER: Inhibition of human GI-ME-N cell growth in a cell viability assay.
SANGER: Inhibition of human GI-ME-N cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| GOTO | IC50 |
73.045 μM
Compound: VX-680
|
SANGER: Inhibition of human GOTO cell growth in a cell viability assay.
SANGER: Inhibition of human GOTO cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| GR-ST | IC50 |
109.992 μM
Compound: VX-680
|
SANGER: Inhibition of human GR-ST cell growth in a cell viability assay.
SANGER: Inhibition of human GR-ST cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| GT3TKB | IC50 |
1.281 μM
Compound: VX-680
|
SANGER: Inhibition of human GT3TKB cell growth in a cell viability assay.
SANGER: Inhibition of human GT3TKB cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| HAL-01 | IC50 |
1.167 μM
Compound: VX-680
|
SANGER: Inhibition of human HAL-01 cell growth in a cell viability assay.
SANGER: Inhibition of human HAL-01 cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| HC-1 | IC50 |
4.695 μM
Compound: VX-680
|
SANGER: Inhibition of human HC-1 cell growth in a cell viability assay.
SANGER: Inhibition of human HC-1 cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| HCC1187 | IC50 |
1.005 μM
Compound: VX-680
|
SANGER: Inhibition of human HCC1187 cell growth in a cell viability assay.
SANGER: Inhibition of human HCC1187 cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| HCC1599 | IC50 |
0.809 μM
Compound: VX-680
|
SANGER: Inhibition of human HCC1599 cell growth in a cell viability assay.
SANGER: Inhibition of human HCC1599 cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| HCC2157 | IC50 |
35.462 μM
Compound: VX-680
|
SANGER: Inhibition of human HCC2157 cell growth in a cell viability assay.
SANGER: Inhibition of human HCC2157 cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| HCC2218 | IC50 |
251.321 μM
Compound: VX-680
|
SANGER: Inhibition of human HCC2218 cell growth in a cell viability assay.
SANGER: Inhibition of human HCC2218 cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| HCE-4 | IC50 |
0.881 μM
Compound: VX-680
|
SANGER: Inhibition of human HCE-4 cell growth in a cell viability assay.
SANGER: Inhibition of human HCE-4 cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| HCE-T | IC50 |
13.005 μM
Compound: VX-680
|
SANGER: Inhibition of human HCE-T cell growth in a cell viability assay.
SANGER: Inhibition of human HCE-T cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| HCT-116 | EC50 |
120 nM
Compound: 1, VX-680
|
Antiproliferative activity against human HCT116 cells after 96 hrs by MTS assay
Antiproliferative activity against human HCT116 cells after 96 hrs by MTS assay
|
[PMID: 23808327] |
| HCT-116 | IC50 |
0.053 μM
Compound: 39, VX-680
|
Antiproliferative activity against human HCT116 cells
Antiproliferative activity against human HCT116 cells
|
[PMID: 18630890] |
| HCT-116 | IC50 |
0.3 μM
Compound: VX-680
|
Cytotoxicity against human HCT116 cells after 48 hrs by MTT assay
Cytotoxicity against human HCT116 cells after 48 hrs by MTT assay
|
[PMID: 22572580] |
| HCT-116 | IC50 |
0.45 μM
Compound: VX 680
|
Cytotoxicity against human HCT116 cells assessed as reduction in cell viability after 48 hrs by MTT assay
Cytotoxicity against human HCT116 cells assessed as reduction in cell viability after 48 hrs by MTT assay
|
[PMID: 30143423] |
| HCT-116 | IC50 |
1.49 μM
Compound: VX-680
|
Antiproliferative activity against human HCT116 cells assessed as reduction in cell viability after 72 hrs by MTT assay
Antiproliferative activity against human HCT116 cells assessed as reduction in cell viability after 72 hrs by MTT assay
|
[PMID: 31862411] |
| HCT-116 | IC50 |
120 nM
Compound: 1, VX-680
|
Antiproliferative activity against human HCT116 cells
Antiproliferative activity against human HCT116 cells
|
[PMID: 23808327] |
| HCT-116 | IC50 |
120 nM
Compound: Tozasertib
|
Cytotoxicity against human HCT116 cells by MTS assay
Cytotoxicity against human HCT116 cells by MTS assay
|
[PMID: 20550212] |
| HCT-116 | IC50 |
2.79 μM
Compound: VX680
|
Antiproliferative activity against human HCT116 cells incubated for 72 hrs by MTT assay
Antiproliferative activity against human HCT116 cells incubated for 72 hrs by MTT assay
|
[PMID: 32941989] |
| HCT-116 | IC50 |
24 nM
Compound: 1, VX- 680, MK-0457
|
Cytotoxicity against human HCT116 cells assessed as number of colonies after 10 to 14 days by colony forming assay
Cytotoxicity against human HCT116 cells assessed as number of colonies after 10 to 14 days by colony forming assay
|
[PMID: 19143567] |
| HCT-116 | IC50 |
28 nM
Compound: VX-680, MK-0457
|
Antiproliferative activity against human HCT116 cells
Antiproliferative activity against human HCT116 cells
|
[PMID: 21802948] |
| HCT-116 | IC50 |
4.32 μM
Compound: VX-680
|
Antiproliferative activity against human HCT116 cells after 48 hrs by CCK8 assay
Antiproliferative activity against human HCT116 cells after 48 hrs by CCK8 assay
|
[PMID: 29358147] |
| HCT-116 | IC50 |
4.32 μM
Compound: VX-680, MK-0457
|
Antiproliferative activity against human HCT116 cells assessed as cell viability after 72 hrs by CCK8 assay
Antiproliferative activity against human HCT116 cells assessed as cell viability after 72 hrs by CCK8 assay
|
[PMID: 24681066] |
| HCT-116 | IC50 |
55 nM
Compound: VX-680, MK-0457
|
Inhibition of Aurora B kinase assessed as reduction in histone H3 phosphorylation in human HCT116 cells
Inhibition of Aurora B kinase assessed as reduction in histone H3 phosphorylation in human HCT116 cells
|
[PMID: 21802948] |
| HCT-15 | IC50 |
1.23 μM
Compound: VX 680
|
Cytotoxicity against human HCT15 cells assessed as reduction in cell viability after 48 hrs by MTT assay
Cytotoxicity against human HCT15 cells assessed as reduction in cell viability after 48 hrs by MTT assay
|
[PMID: 30143423] |
| HCT-8 | IC50 |
44.6 μM
Compound: VX-680
|
Cytotoxicity against human HCT8 cells after 48 hrs by MTT assay
Cytotoxicity against human HCT8 cells after 48 hrs by MTT assay
|
[PMID: 25812967] |
| HDLM-2 | IC50 |
380.236 μM
Compound: VX-680
|
SANGER: Inhibition of human HDLM-2 cell growth in a cell viability assay.
SANGER: Inhibition of human HDLM-2 cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| HD-MY-Z | IC50 |
46.461 μM
Compound: VX-680
|
SANGER: Inhibition of human HD-MY-Z cell growth in a cell viability assay.
SANGER: Inhibition of human HD-MY-Z cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| HEL | IC50 |
3.632 μM
Compound: VX-680
|
SANGER: Inhibition of human HEL cell growth in a cell viability assay.
SANGER: Inhibition of human HEL cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| HeLa | GI50 |
46.2 μM
Compound: VX-680
|
Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay
Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay
|
[PMID: 30502115] |
| HeLa | IC50 |
0.013 μM
Compound: VX-680
|
Inhibition of Aurora A phosphorylation at Thr288 residue in human HeLa cells after 12 hrs by ELISA
Inhibition of Aurora A phosphorylation at Thr288 residue in human HeLa cells after 12 hrs by ELISA
|
[PMID: 30502115] |
| HeLa | IC50 |
0.148 μM
Compound: VX-680
|
Inhibition of Aurora B phosphorylation at Thr232 residue in human HeLa cells after 12 hrs by ELISA
Inhibition of Aurora B phosphorylation at Thr232 residue in human HeLa cells after 12 hrs by ELISA
|
[PMID: 30502115] |
| HeLa | IC50 |
0.261 μM
Compound: VX-680
|
Inhibition of Aurora A in human HeLa cells after 12 hrs by ELISA method
Inhibition of Aurora A in human HeLa cells after 12 hrs by ELISA method
|
[PMID: 25812967] |
| HeLa | IC50 |
0.453 μM
Compound: VX-680
|
Inhibition of Aurora B in human HeLa cells after 12 hrs by ELISA method
Inhibition of Aurora B in human HeLa cells after 12 hrs by ELISA method
|
[PMID: 25812967] |
| HeLa | IC50 |
2.93 μM
Compound: VX-680
|
Antiproliferative activity against human HeLa cells after 48 hrs by CCK8 assay
Antiproliferative activity against human HeLa cells after 48 hrs by CCK8 assay
|
[PMID: 29358147] |
| HeLa | IC50 |
2.93 μM
Compound: VX-680, MK-0457
|
Antiproliferative activity against human HeLa cells assessed as cell viability after 72 hrs by CCK8 assay
Antiproliferative activity against human HeLa cells assessed as cell viability after 72 hrs by CCK8 assay
|
[PMID: 24681066] |
| HeLa | IC50 |
27.3 μM
Compound: VX-680
|
Cytotoxicity against human HeLa cells after 48 hrs by MTT assay
Cytotoxicity against human HeLa cells after 48 hrs by MTT assay
|
[PMID: 25812967] |
| HeLa | IC50 |
46.2 μM
Compound: VX-680
|
Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay
Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay
|
[PMID: 30728112] |
| HeLa | IC50 |
6.24 μM
Compound: VX-680
|
Anticancer activity against human HeLa cells assessed as reduction in cell viability measured after 24 hrs by MTT assay
Anticancer activity against human HeLa cells assessed as reduction in cell viability measured after 24 hrs by MTT assay
|
[PMID: 35476959] |
| HeLa | IC50 |
9.5 μM
Compound: VX-680
|
Antiproliferative activity against human HeLa cells assessed as cell growth inhibition after 72 hrs by MTT assay
Antiproliferative activity against human HeLa cells assessed as cell growth inhibition after 72 hrs by MTT assay
|
[PMID: 32035750] |
| HepG2 | GI50 |
53.3 μM
Compound: VX-680
|
Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay
Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay
|
[PMID: 30502115] |
| HepG2 | IC50 |
12.8 μM
Compound: VX-680
|
Antiproliferative activity against human HepG2 cells assessed as cell growth inhibition after 72 hrs by MTT assay
Antiproliferative activity against human HepG2 cells assessed as cell growth inhibition after 72 hrs by MTT assay
|
[PMID: 32035750] |
| HepG2 | IC50 |
16.11 μM
Compound: VX680
|
Antiproliferative activity against human HepG2 cells incubated for 72 hrs by MTT assay
Antiproliferative activity against human HepG2 cells incubated for 72 hrs by MTT assay
|
[PMID: 32941989] |
| HepG2 | IC50 |
18.01 μM
Compound: VX-680
|
Anticancer activity against human HepG2 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay
Anticancer activity against human HepG2 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay
|
[PMID: 35476959] |
| HepG2 | IC50 |
53.3 μM
Compound: VX-680
|
Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay
Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay
|
[PMID: 30728112] |
| HepG2 | IC50 |
63.4 μM
Compound: VX-680
|
Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay
Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay
|
[PMID: 25812967] |
| HH | IC50 |
17.196 μM
Compound: VX-680
|
SANGER: Inhibition of human HH cell growth in a cell viability assay.
SANGER: Inhibition of human HH cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| HL-60 | IC50 |
0.0382 μM
Compound: VX-680, MK-0457
|
Antiproliferative activity against human HL60 cells assessed as cell viability after 72 hrs by CCK8 assay
Antiproliferative activity against human HL60 cells assessed as cell viability after 72 hrs by CCK8 assay
|
[PMID: 24681066] |
| HL-60 | IC50 |
1.066 μM
Compound: VX-680
|
SANGER: Inhibition of human HL-60 cell growth in a cell viability assay.
SANGER: Inhibition of human HL-60 cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| HL-60 | IC50 |
1.88 μM
Compound: VX-680
|
Anticancer activity against human HL-60 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay
Anticancer activity against human HL-60 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay
|
[PMID: 35476959] |
| HOP-62 | IC50 |
0.863 μM
Compound: VX-680
|
SANGER: Inhibition of human HOP-62 cell growth in a cell viability assay.
SANGER: Inhibition of human HOP-62 cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| HT | IC50 |
136.722 μM
Compound: VX-680
|
SANGER: Inhibition of human HT cell growth in a cell viability assay.
SANGER: Inhibition of human HT cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| HT-144 | IC50 |
0.638 μM
Compound: VX-680
|
SANGER: Inhibition of human HT-144 cell growth in a cell viability assay.
SANGER: Inhibition of human HT-144 cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| HT-29 | IC50 |
0.15 μM
Compound: 39, VX-680
|
Antiproliferative activity against human HT29 cells
Antiproliferative activity against human HT29 cells
|
[PMID: 18630890] |
| IA-LM | IC50 |
7.859 μM
Compound: VX-680
|
SANGER: Inhibition of human IA-LM cell growth in a cell viability assay.
SANGER: Inhibition of human IA-LM cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| IM-9 | IC50 |
447.539 μM
Compound: VX-680
|
SANGER: Inhibition of human IM-9 cell growth in a cell viability assay.
SANGER: Inhibition of human IM-9 cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| IMR-5 | IC50 |
0.355 μM
Compound: VX-680
|
SANGER: Inhibition of human IMR-5 cell growth in a cell viability assay.
SANGER: Inhibition of human IMR-5 cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| IST-MEL1 | IC50 |
13.579 μM
Compound: VX-680
|
SANGER: Inhibition of human IST-MEL1 cell growth in a cell viability assay.
SANGER: Inhibition of human IST-MEL1 cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| IST-MES1 | IC50 |
19.666 μM
Compound: VX-680
|
SANGER: Inhibition of human IST-MES1 cell growth in a cell viability assay.
SANGER: Inhibition of human IST-MES1 cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| IST-SL1 | IC50 |
2.298 μM
Compound: VX-680
|
SANGER: Inhibition of human IST-SL1 cell growth in a cell viability assay.
SANGER: Inhibition of human IST-SL1 cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| IST-SL2 | IC50 |
0.72 μM
Compound: VX-680
|
SANGER: Inhibition of human IST-SL2 cell growth in a cell viability assay.
SANGER: Inhibition of human IST-SL2 cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| JAR | IC50 |
38.245 μM
Compound: VX-680
|
SANGER: Inhibition of human JAR cell growth in a cell viability assay.
SANGER: Inhibition of human JAR cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| JIYOYE | IC50 |
15.633 μM
Compound: VX-680
|
SANGER: Inhibition of human JiyoyeP-2003 cell growth in a cell viability assay.
SANGER: Inhibition of human JiyoyeP-2003 cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| J-RT3-T3-5 | IC50 |
63.539 μM
Compound: VX-680
|
SANGER: Inhibition of human J-RT3-T3-5 cell growth in a cell viability assay.
SANGER: Inhibition of human J-RT3-T3-5 cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| JVM-2 | IC50 |
72.328 μM
Compound: VX-680
|
SANGER: Inhibition of human JVM-2 cell growth in a cell viability assay.
SANGER: Inhibition of human JVM-2 cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| JVM-3 | IC50 |
432.984 μM
Compound: VX-680
|
SANGER: Inhibition of human JVM-3 cell growth in a cell viability assay.
SANGER: Inhibition of human JVM-3 cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| K052 | IC50 |
0.195 μM
Compound: VX-680
|
SANGER: Inhibition of human K052 cell growth in a cell viability assay.
SANGER: Inhibition of human K052 cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| K5 | IC50 |
2.403 μM
Compound: VX-680
|
SANGER: Inhibition of human K5 cell growth in a cell viability assay.
SANGER: Inhibition of human K5 cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| K562 | IC50 |
0.079 μM
Compound: VX-680
|
Antiproliferative activity against human K562 cells after 48 hrs by CCK8 assay
Antiproliferative activity against human K562 cells after 48 hrs by CCK8 assay
|
[PMID: 29358147] |
| K562 | IC50 |
0.0791 μM
Compound: VX-680, MK-0457
|
Antiproliferative activity against human K562 cells assessed as cell viability after 72 hrs by CCK8 assay
Antiproliferative activity against human K562 cells assessed as cell viability after 72 hrs by CCK8 assay
|
[PMID: 24681066] |
| K562 | IC50 |
0.435 μM
Compound: VX-680
|
SANGER: Inhibition of human K-562 cell growth in a cell viability assay.
SANGER: Inhibition of human K-562 cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| KALS-1 | IC50 |
8.839 μM
Compound: VX-680
|
SANGER: Inhibition of human KALS-1 cell growth in a cell viability assay.
SANGER: Inhibition of human KALS-1 cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| KARPAS-299 | IC50 |
353.77 μM
Compound: VX-680
|
SANGER: Inhibition of human KARPAS-299 cell growth in a cell viability assay.
SANGER: Inhibition of human KARPAS-299 cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| KARPAS-422 | IC50 |
0.373 μM
Compound: VX-680
|
SANGER: Inhibition of human KARPAS-422 cell growth in a cell viability assay.
SANGER: Inhibition of human KARPAS-422 cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| KARPAS-45 | IC50 |
2.027 μM
Compound: VX-680
|
SANGER: Inhibition of human KARPAS-45 cell growth in a cell viability assay.
SANGER: Inhibition of human KARPAS-45 cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| Kasumi 1 | IC50 |
500.567 μM
Compound: VX-680
|
SANGER: Inhibition of human KASUMI-1 cell growth in a cell viability assay.
SANGER: Inhibition of human KASUMI-1 cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| KE-37 | IC50 |
0.521 μM
Compound: VX-680
|
SANGER: Inhibition of human KE-37 cell growth in a cell viability assay.
SANGER: Inhibition of human KE-37 cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| KG-1 | IC50 |
12.655 μM
Compound: VX-680
|
SANGER: Inhibition of human KG-1 cell growth in a cell viability assay.
SANGER: Inhibition of human KG-1 cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| KGN | IC50 |
0.9 μM
Compound: VX-680
|
SANGER: Inhibition of human KGN cell growth in a cell viability assay.
SANGER: Inhibition of human KGN cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| KINGS-1 | IC50 |
57.579 μM
Compound: VX-680
|
SANGER: Inhibition of human KINGS-1 cell growth in a cell viability assay.
SANGER: Inhibition of human KINGS-1 cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| KLE | IC50 |
22.19 μM
Compound: VX-680
|
SANGER: Inhibition of human KLE cell growth in a cell viability assay.
SANGER: Inhibition of human KLE cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| KM12 | IC50 |
0.264 μM
Compound: VX-680
|
SANGER: Inhibition of human KM12 cell growth in a cell viability assay.
SANGER: Inhibition of human KM12 cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| KM-H2 | IC50 |
7.185 μM
Compound: VX-680
|
SANGER: Inhibition of human KM-H2 cell growth in a cell viability assay.
SANGER: Inhibition of human KM-H2 cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| KMOE-2 | IC50 |
55.446 μM
Compound: VX-680
|
SANGER: Inhibition of human KMOE-2 cell growth in a cell viability assay.
SANGER: Inhibition of human KMOE-2 cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| KMS-12-PE | IC50 |
285.426 μM
Compound: VX-680
|
SANGER: Inhibition of human KMS-12-PE cell growth in a cell viability assay.
SANGER: Inhibition of human KMS-12-PE cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| KNS-42 | IC50 |
30.896 μM
Compound: VX-680
|
SANGER: Inhibition of human KNS-42 cell growth in a cell viability assay.
SANGER: Inhibition of human KNS-42 cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| KNS-81-FD | IC50 |
34.546 μM
Compound: VX-680
|
SANGER: Inhibition of human KNS-81-FD cell growth in a cell viability assay.
SANGER: Inhibition of human KNS-81-FD cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| KP-N-RT-BM-1 | IC50 |
25.475 μM
Compound: VX-680
|
SANGER: Inhibition of human KP-N-RT-BM-1 cell growth in a cell viability assay.
SANGER: Inhibition of human KP-N-RT-BM-1 cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| KP-N-YS | IC50 |
0.544 μM
Compound: VX-680
|
SANGER: Inhibition of human KP-N-YS cell growth in a cell viability assay.
SANGER: Inhibition of human KP-N-YS cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| KS-1 | IC50 |
0.238 μM
Compound: VX-680
|
SANGER: Inhibition of human KS-1 cell growth in a cell viability assay.
SANGER: Inhibition of human KS-1 cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| KU812 cell line | IC50 |
41.507 μM
Compound: VX-680
|
SANGER: Inhibition of human KU812 cell growth in a cell viability assay.
SANGER: Inhibition of human KU812 cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| KURAMOCHI | IC50 |
1.789 μM
Compound: VX-680
|
SANGER: Inhibition of human KURAMOCHI cell growth in a cell viability assay.
SANGER: Inhibition of human KURAMOCHI cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| KY821 | IC50 |
9.775 μM
Compound: VX-680
|
SANGER: Inhibition of human KY821 cell growth in a cell viability assay.
SANGER: Inhibition of human KY821 cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| L-363 | IC50 |
46.881 μM
Compound: VX-680
|
SANGER: Inhibition of human L-363 cell growth in a cell viability assay.
SANGER: Inhibition of human L-363 cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| L-428 | IC50 |
388.804 μM
Compound: VX-680
|
SANGER: Inhibition of human L-428 cell growth in a cell viability assay.
SANGER: Inhibition of human L-428 cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| L-540 | IC50 |
60.805 μM
Compound: VX-680
|
SANGER: Inhibition of human L-540 cell growth in a cell viability assay.
SANGER: Inhibition of human L-540 cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| LAMA-84 | IC50 |
0.352 μM
Compound: VX-680
|
SANGER: Inhibition of human LAMA-84 cell growth in a cell viability assay.
SANGER: Inhibition of human LAMA-84 cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| LAN-6 | IC50 |
126.554 μM
Compound: VX-680
|
SANGER: Inhibition of human LAN-6 cell growth in a cell viability assay.
SANGER: Inhibition of human LAN-6 cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| LB1047-RCC | IC50 |
2.881 μM
Compound: VX-680
|
SANGER: Inhibition of human LB1047-RCC cell growth in a cell viability assay.
SANGER: Inhibition of human LB1047-RCC cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| LB2241-RCC | IC50 |
138.478 μM
Compound: VX-680
|
SANGER: Inhibition of human LB2241-RCC cell growth in a cell viability assay.
SANGER: Inhibition of human LB2241-RCC cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| LB2518-MEL | IC50 |
27.177 μM
Compound: VX-680
|
SANGER: Inhibition of human LB2518-MEL cell growth in a cell viability assay.
SANGER: Inhibition of human LB2518-MEL cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| LB373-MEL-D | IC50 |
11.383 μM
Compound: VX-680
|
SANGER: Inhibition of human LB373-MEL-D cell growth in a cell viability assay.
SANGER: Inhibition of human LB373-MEL-D cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| LB647-SCLC | IC50 |
0.215 μM
Compound: VX-680
|
SANGER: Inhibition of human LB647-SCLC cell growth in a cell viability assay.
SANGER: Inhibition of human LB647-SCLC cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| LB771-HNC | IC50 |
95.455 μM
Compound: VX-680
|
SANGER: Inhibition of human LB771-HNC cell growth in a cell viability assay.
SANGER: Inhibition of human LB771-HNC cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| LB831-BLC | IC50 |
25.153 μM
Compound: VX-680
|
SANGER: Inhibition of human LB831-BLC cell growth in a cell viability assay.
SANGER: Inhibition of human LB831-BLC cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| LB996-RCC | IC50 |
31.17 μM
Compound: VX-680
|
SANGER: Inhibition of human LB996-RCC cell growth in a cell viability assay.
SANGER: Inhibition of human LB996-RCC cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| LC-1F | IC50 |
160.979 μM
Compound: VX-680
|
SANGER: Inhibition of human LC-1F cell growth in a cell viability assay.
SANGER: Inhibition of human LC-1F cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| LC-2-ad | IC50 |
0.088 μM
Compound: VX-680
|
SANGER: Inhibition of human LC-2-ad cell growth in a cell viability assay.
SANGER: Inhibition of human LC-2-ad cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| LC4-1 | IC50 |
12.771 μM
Compound: VX-680
|
SANGER: Inhibition of human LC4-1 cell growth in a cell viability assay.
SANGER: Inhibition of human LC4-1 cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| LNCaP-Clone-FGC | IC50 |
532.537 μM
Compound: VX-680
|
SANGER: Inhibition of human LNCaP-Clone-FGC cell growth in a cell viability assay.
SANGER: Inhibition of human LNCaP-Clone-FGC cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| LOUCY | IC50 |
3.187 μM
Compound: VX-680
|
SANGER: Inhibition of human LOUCY cell growth in a cell viability assay.
SANGER: Inhibition of human LOUCY cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| LoVo | GI50 |
45.3 μM
Compound: VX-680
|
Antiproliferative activity against human LoVo cells after 48 hrs by MTT assay
Antiproliferative activity against human LoVo cells after 48 hrs by MTT assay
|
[PMID: 30502115] |
| LoVo | IC50 |
13.6 μM
Compound: VX-680
|
Antiproliferative activity against human LoVo cells assessed as cell growth inhibition after 72 hrs by MTT assay
Antiproliferative activity against human LoVo cells assessed as cell growth inhibition after 72 hrs by MTT assay
|
[PMID: 32035750] |
| LoVo | IC50 |
45.3 μM
Compound: VX-680
|
Antiproliferative activity against human LoVo cells after 48 hrs by MTT assay
Antiproliferative activity against human LoVo cells after 48 hrs by MTT assay
|
[PMID: 30728112] |
| LOX IMVI | IC50 |
143.123 μM
Compound: VX-680
|
SANGER: Inhibition of human LOXIMVI cell growth in a cell viability assay.
SANGER: Inhibition of human LOXIMVI cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| LP-1 | IC50 |
21.343 μM
Compound: VX-680
|
SANGER: Inhibition of human LP-1 cell growth in a cell viability assay.
SANGER: Inhibition of human LP-1 cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| LS-1034 | IC50 |
6.757 μM
Compound: VX-680
|
SANGER: Inhibition of human LS-1034 cell growth in a cell viability assay.
SANGER: Inhibition of human LS-1034 cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| LS-123 | IC50 |
14.159 μM
Compound: VX-680
|
SANGER: Inhibition of human LS-123 cell growth in a cell viability assay.
SANGER: Inhibition of human LS-123 cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| LS-411N | IC50 |
0.578 μM
Compound: VX-680
|
SANGER: Inhibition of human LS-411N cell growth in a cell viability assay.
SANGER: Inhibition of human LS-411N cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| LS-513 | IC50 |
45.916 μM
Compound: VX-680
|
SANGER: Inhibition of human LS-513 cell growth in a cell viability assay.
SANGER: Inhibition of human LS-513 cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| LU-134-A | IC50 |
2.893 μM
Compound: VX-680
|
SANGER: Inhibition of human LU-134-A cell growth in a cell viability assay.
SANGER: Inhibition of human LU-134-A cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| LU-139 | IC50 |
4.618 μM
Compound: VX-680
|
SANGER: Inhibition of human LU-139 cell growth in a cell viability assay.
SANGER: Inhibition of human LU-139 cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| LU-165 | IC50 |
315.786 μM
Compound: VX-680
|
SANGER: Inhibition of human LU-165 cell growth in a cell viability assay.
SANGER: Inhibition of human LU-165 cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| Lu-65 | IC50 |
544.656 μM
Compound: VX-680
|
SANGER: Inhibition of human LU-65 cell growth in a cell viability assay.
SANGER: Inhibition of human LU-65 cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| LXF-289 cell line | IC50 |
0.404 μM
Compound: VX-680
|
SANGER: Inhibition of human LXF-289 cell growth in a cell viability assay.
SANGER: Inhibition of human LXF-289 cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| MC116 | IC50 |
0.85 μM
Compound: VX-680
|
SANGER: Inhibition of human MC116 cell growth in a cell viability assay.
SANGER: Inhibition of human MC116 cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| MC-CAR | IC50 |
5.068 μM
Compound: VX-680
|
SANGER: Inhibition of human MC-CAR cell growth in a cell viability assay.
SANGER: Inhibition of human MC-CAR cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| MCF7 | IC50 |
0.048 μM
Compound: 39, VX-680
|
Antiproliferative activity against human MCF7 cells
Antiproliferative activity against human MCF7 cells
|
[PMID: 18630890] |
| MCF7 | IC50 |
0.38 μM
Compound: VX-680
|
Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay
Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay
|
[PMID: 22572580] |
| MCF7 | IC50 |
1.02 μM
Compound: VX-680
|
Anticancer activity against human MCF7 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay
Anticancer activity against human MCF7 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay
|
[PMID: 35476959] |
| MCF7 | IC50 |
1.3 μM
Compound: VX-680
|
Antiproliferative activity against human MCF7 cells after 48 hrs by CCK8 assay
Antiproliferative activity against human MCF7 cells after 48 hrs by CCK8 assay
|
[PMID: 29358147] |
| MCF7 | IC50 |
1.3 μM
Compound: VX-680, MK-0457
|
Antiproliferative activity against human MCF7 cells assessed as cell viability after 72 hrs by CCK8 assay
Antiproliferative activity against human MCF7 cells assessed as cell viability after 72 hrs by CCK8 assay
|
[PMID: 24681066] |
| MCF7 | IC50 |
17.39 μM
Compound: VX-680
|
Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability after 72 hrs by MTT assay
Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability after 72 hrs by MTT assay
|
[PMID: 31862411] |
| MCF7 | IC50 |
39.78 μM
Compound: VX680
|
Antiproliferative activity against human MCF-7 cells incubated for 72 hrs by MTT assay
Antiproliferative activity against human MCF-7 cells incubated for 72 hrs by MTT assay
|
[PMID: 32941989] |
| MDA-MB-134-VI | IC50 |
113.284 μM
Compound: VX-680
|
SANGER: Inhibition of human MDA-MB-134-VI cell growth in a cell viability assay.
SANGER: Inhibition of human MDA-MB-134-VI cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| MDA-MB-231 | IC50 |
0.127 μM
Compound: VX-680
|
Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by CCK8 assay
Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by CCK8 assay
|
[PMID: 29358147] |
| MDA-MB-231 | IC50 |
0.127 μM
Compound: VX-680, MK-0457
|
Antiproliferative activity against human MDA-MB-231 cells assessed as cell viability after 72 hrs by CCK8 assay
Antiproliferative activity against human MDA-MB-231 cells assessed as cell viability after 72 hrs by CCK8 assay
|
[PMID: 24681066] |
| MEG-01 | IC50 |
0.278 μM
Compound: VX-680
|
SANGER: Inhibition of human MEG-01 cell growth in a cell viability assay.
SANGER: Inhibition of human MEG-01 cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| MFH-ino | IC50 |
0.01 μM
Compound: VX-680
|
SANGER: Inhibition of human MFH-ino cell growth in a cell viability assay.
SANGER: Inhibition of human MFH-ino cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| MFM-223 | IC50 |
326.314 μM
Compound: VX-680
|
SANGER: Inhibition of human MFM-223 cell growth in a cell viability assay.
SANGER: Inhibition of human MFM-223 cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| MHH-CALL-2 | IC50 |
393.197 μM
Compound: VX-680
|
SANGER: Inhibition of human MHH-CALL-2 cell growth in a cell viability assay.
SANGER: Inhibition of human MHH-CALL-2 cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| MHH-NB-11 | IC50 |
3.953 μM
Compound: VX-680
|
SANGER: Inhibition of human MHH-NB-11 cell growth in a cell viability assay.
SANGER: Inhibition of human MHH-NB-11 cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| MHH-PREB-1 | IC50 |
28.073 μM
Compound: VX-680
|
SANGER: Inhibition of human MHH-PREB-1 cell growth in a cell viability assay.
SANGER: Inhibition of human MHH-PREB-1 cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| MLMA | IC50 |
82.009 μM
Compound: VX-680
|
SANGER: Inhibition of human MLMA cell growth in a cell viability assay.
SANGER: Inhibition of human MLMA cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| MMAC-SF | IC50 |
4.025 μM
Compound: VX-680
|
SANGER: Inhibition of human MMAC-SF cell growth in a cell viability assay.
SANGER: Inhibition of human MMAC-SF cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| MN-60 | IC50 |
191.241 μM
Compound: VX-680
|
SANGER: Inhibition of human MN-60 cell growth in a cell viability assay.
SANGER: Inhibition of human MN-60 cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| Mo | IC50 |
339.664 μM
Compound: VX-680
|
SANGER: Inhibition of human Mo-T cell growth in a cell viability assay.
SANGER: Inhibition of human Mo-T cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| MOLT-16 | IC50 |
1.354 μM
Compound: VX-680
|
SANGER: Inhibition of human MOLT-16 cell growth in a cell viability assay.
SANGER: Inhibition of human MOLT-16 cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| MOLT-4 | IC50 |
0.0212 μM
Compound: VX-680, MK-0457
|
Antiproliferative activity against human MOLT4 cells assessed as cell viability after 72 hrs by CCK8 assay
Antiproliferative activity against human MOLT4 cells assessed as cell viability after 72 hrs by CCK8 assay
|
[PMID: 24681066] |
| MOLT-4 | IC50 |
0.233 μM
Compound: VX-680
|
SANGER: Inhibition of human MOLT-4 cell growth in a cell viability assay.
SANGER: Inhibition of human MOLT-4 cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| MONO-MAC-6 | IC50 |
0.079 μM
Compound: VX-680
|
SANGER: Inhibition of human MONO-MAC-6 cell growth in a cell viability assay.
SANGER: Inhibition of human MONO-MAC-6 cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| MPP-89 | IC50 |
25.531 μM
Compound: VX-680
|
SANGER: Inhibition of human MPP-89 cell growth in a cell viability assay.
SANGER: Inhibition of human MPP-89 cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| MRK-nu-1 | IC50 |
0.381 μM
Compound: VX-680
|
SANGER: Inhibition of human MRK-nu-1 cell growth in a cell viability assay.
SANGER: Inhibition of human MRK-nu-1 cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| MS-1 | IC50 |
158.313 μM
Compound: VX-680
|
SANGER: Inhibition of human MS-1 cell growth in a cell viability assay.
SANGER: Inhibition of human MS-1 cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| MSTO-211H | IC50 |
336.798 μM
Compound: VX-680
|
SANGER: Inhibition of human MSTO-211H cell growth in a cell viability assay.
SANGER: Inhibition of human MSTO-211H cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| MZ1-PC | IC50 |
3.992 μM
Compound: VX-680
|
SANGER: Inhibition of human MZ1-PC cell growth in a cell viability assay.
SANGER: Inhibition of human MZ1-PC cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| MZ2-MEL | IC50 |
28.614 μM
Compound: VX-680
|
SANGER: Inhibition of human MZ2-MEL cell growth in a cell viability assay.
SANGER: Inhibition of human MZ2-MEL cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| MZ7-mel | IC50 |
14.443 μM
Compound: VX-680
|
SANGER: Inhibition of human MZ7-mel cell growth in a cell viability assay.
SANGER: Inhibition of human MZ7-mel cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| NALM-6 | IC50 |
0.026 μM
Compound: VX-680
|
SANGER: Inhibition of human NALM-6 cell growth in a cell viability assay.
SANGER: Inhibition of human NALM-6 cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| NB1 | IC50 |
12.29 μM
Compound: VX-680
|
SANGER: Inhibition of human NB1 cell growth in a cell viability assay.
SANGER: Inhibition of human NB1 cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| NB10 | IC50 |
244.83 μM
Compound: VX-680
|
SANGER: Inhibition of human NB10 cell growth in a cell viability assay.
SANGER: Inhibition of human NB10 cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| NB13 | IC50 |
0.28 μM
Compound: VX-680
|
SANGER: Inhibition of human NB13 cell growth in a cell viability assay.
SANGER: Inhibition of human NB13 cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| NB14 | IC50 |
215.389 μM
Compound: VX-680
|
SANGER: Inhibition of human NB14 cell growth in a cell viability assay.
SANGER: Inhibition of human NB14 cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| NB17 | IC50 |
2.293 μM
Compound: VX-680
|
SANGER: Inhibition of human NB17 cell growth in a cell viability assay.
SANGER: Inhibition of human NB17 cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| NB5 | IC50 |
1.642 μM
Compound: VX-680
|
SANGER: Inhibition of human NB5 cell growth in a cell viability assay.
SANGER: Inhibition of human NB5 cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| NB6 | IC50 |
0.773 μM
Compound: VX-680
|
SANGER: Inhibition of human NB6 cell growth in a cell viability assay.
SANGER: Inhibition of human NB6 cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| NB69 | IC50 |
11.77 μM
Compound: VX-680
|
SANGER: Inhibition of human NB69 cell growth in a cell viability assay.
SANGER: Inhibition of human NB69 cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| NB7 | IC50 |
211.002 μM
Compound: VX-680
|
SANGER: Inhibition of human NB7 cell growth in a cell viability assay.
SANGER: Inhibition of human NB7 cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| NCCIT | IC50 |
11.058 μM
Compound: VX-680
|
SANGER: Inhibition of human NCCIT cell growth in a cell viability assay.
SANGER: Inhibition of human NCCIT cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| NCI-H1092 | IC50 |
66.521 μM
Compound: VX-680
|
SANGER: Inhibition of human NCI-H1092 cell growth in a cell viability assay.
SANGER: Inhibition of human NCI-H1092 cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| NCI-H1155 | IC50 |
37.815 μM
Compound: VX-680
|
SANGER: Inhibition of human NCI-H1155 cell growth in a cell viability assay.
SANGER: Inhibition of human NCI-H1155 cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| NCI-H128 | IC50 |
325.21 μM
Compound: VX-680
|
SANGER: Inhibition of human NCI-H128 cell growth in a cell viability assay.
SANGER: Inhibition of human NCI-H128 cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| NCI-H1304 | IC50 |
1.831 μM
Compound: VX-680
|
SANGER: Inhibition of human NCI-H1304 cell growth in a cell viability assay.
SANGER: Inhibition of human NCI-H1304 cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| NCI-H1355 | IC50 |
11.943 μM
Compound: VX-680
|
SANGER: Inhibition of human NCI-H1355 cell growth in a cell viability assay.
SANGER: Inhibition of human NCI-H1355 cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| NCI-H1395 | IC50 |
239.3 μM
Compound: VX-680
|
SANGER: Inhibition of human NCI-H1395 cell growth in a cell viability assay.
SANGER: Inhibition of human NCI-H1395 cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| NCI-H1417 | IC50 |
14.305 μM
Compound: VX-680
|
SANGER: Inhibition of human NCI-H1417 cell growth in a cell viability assay.
SANGER: Inhibition of human NCI-H1417 cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| NCI-H1436 | IC50 |
7.699 μM
Compound: VX-680
|
SANGER: Inhibition of human NCI-H1436 cell growth in a cell viability assay.
SANGER: Inhibition of human NCI-H1436 cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| NCI-H1522 | IC50 |
68.171 μM
Compound: VX-680
|
SANGER: Inhibition of human NCI-H1522 cell growth in a cell viability assay.
SANGER: Inhibition of human NCI-H1522 cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| NCI-H1581 | IC50 |
6.784 μM
Compound: VX-680
|
SANGER: Inhibition of human NCI-H1581 cell growth in a cell viability assay.
SANGER: Inhibition of human NCI-H1581 cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| NCI-H1648 | IC50 |
5.815 μM
Compound: VX-680
|
SANGER: Inhibition of human NCI-H1648 cell growth in a cell viability assay.
SANGER: Inhibition of human NCI-H1648 cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| NCI-H1650 | IC50 |
94.805 μM
Compound: VX-680
|
SANGER: Inhibition of human NCI-H1650 cell growth in a cell viability assay.
SANGER: Inhibition of human NCI-H1650 cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| NCI-H1694 | IC50 |
44.947 μM
Compound: VX-680
|
SANGER: Inhibition of human NCI-H1694 cell growth in a cell viability assay.
SANGER: Inhibition of human NCI-H1694 cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| NCI-H1770 | IC50 |
8.903 μM
Compound: VX-680
|
SANGER: Inhibition of human NCI-H1770 cell growth in a cell viability assay.
SANGER: Inhibition of human NCI-H1770 cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| NCI-H1838 | IC50 |
275.603 μM
Compound: VX-680
|
SANGER: Inhibition of human NCI-H1838 cell growth in a cell viability assay.
SANGER: Inhibition of human NCI-H1838 cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| NCI-H187 | IC50 |
0.641 μM
Compound: VX-680
|
SANGER: Inhibition of human NCI-H187 cell growth in a cell viability assay.
SANGER: Inhibition of human NCI-H187 cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| NCI-H1882 | IC50 |
12.407 μM
Compound: VX-680
|
SANGER: Inhibition of human NCI-H1882 cell growth in a cell viability assay.
SANGER: Inhibition of human NCI-H1882 cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| NCI-H1963 | IC50 |
1.706 μM
Compound: VX-680
|
SANGER: Inhibition of human NCI-H1963 cell growth in a cell viability assay.
SANGER: Inhibition of human NCI-H1963 cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| NCI-H2081 | IC50 |
53.989 μM
Compound: VX-680
|
SANGER: Inhibition of human NCI-H2081 cell growth in a cell viability assay.
SANGER: Inhibition of human NCI-H2081 cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| NCI-H209 | IC50 |
2.913 μM
Compound: VX-680
|
SANGER: Inhibition of human NCI-H209 cell growth in a cell viability assay.
SANGER: Inhibition of human NCI-H209 cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| NCI-H2107 | IC50 |
2.837 μM
Compound: VX-680
|
SANGER: Inhibition of human NCI-H2107 cell growth in a cell viability assay.
SANGER: Inhibition of human NCI-H2107 cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| NCI-H2126 | IC50 |
5.646 μM
Compound: VX-680
|
SANGER: Inhibition of human NCI-H2126 cell growth in a cell viability assay.
SANGER: Inhibition of human NCI-H2126 cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| NCI-H2141 | IC50 |
55.563 μM
Compound: VX-680
|
SANGER: Inhibition of human NCI-H2141 cell growth in a cell viability assay.
SANGER: Inhibition of human NCI-H2141 cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| NCI-H2171 | IC50 |
3.924 μM
Compound: VX-680
|
SANGER: Inhibition of human NCI-H2171 cell growth in a cell viability assay.
SANGER: Inhibition of human NCI-H2171 cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| NCI-H2196 | IC50 |
181.8 μM
Compound: VX-680
|
SANGER: Inhibition of human NCI-H2196 cell growth in a cell viability assay.
SANGER: Inhibition of human NCI-H2196 cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| NCI-H226 | IC50 |
110.169 μM
Compound: VX-680
|
SANGER: Inhibition of human NCI-H226 cell growth in a cell viability assay.
SANGER: Inhibition of human NCI-H226 cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| NCI-H23 | IC50 |
71.449 μM
Compound: VX-680
|
SANGER: Inhibition of human NCI-H23 cell growth in a cell viability assay.
SANGER: Inhibition of human NCI-H23 cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| NCI-H322M | IC50 |
404.085 μM
Compound: VX-680
|
SANGER: Inhibition of human NCI-H322M cell growth in a cell viability assay.
SANGER: Inhibition of human NCI-H322M cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| NCI-H345 | IC50 |
48.468 μM
Compound: VX-680
|
SANGER: Inhibition of human NCI-H345 cell growth in a cell viability assay.
SANGER: Inhibition of human NCI-H345 cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| NCI-H446 | IC50 |
51.524 μM
Compound: VX-680
|
SANGER: Inhibition of human NCI-H446 cell growth in a cell viability assay.
SANGER: Inhibition of human NCI-H446 cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| NCI-H510A | IC50 |
0.438 μM
Compound: VX-680
|
SANGER: Inhibition of human NCI-H510A cell growth in a cell viability assay.
SANGER: Inhibition of human NCI-H510A cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| NCI-H524 | IC50 |
0.511 μM
Compound: VX-680
|
SANGER: Inhibition of human NCI-H524 cell growth in a cell viability assay.
SANGER: Inhibition of human NCI-H524 cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| NCI-H526 | IC50 |
8.256 μM
Compound: VX-680
|
SANGER: Inhibition of human NCI-H526 cell growth in a cell viability assay.
SANGER: Inhibition of human NCI-H526 cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| NCI-H64 | IC50 |
288.067 μM
Compound: VX-680
|
SANGER: Inhibition of human NCI-H64 cell growth in a cell viability assay.
SANGER: Inhibition of human NCI-H64 cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| NCI-H69 | IC50 |
65.892 μM
Compound: VX-680
|
SANGER: Inhibition of human NCI-H69 cell growth in a cell viability assay.
SANGER: Inhibition of human NCI-H69 cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| NCI-H716 | IC50 |
370.996 μM
Compound: VX-680
|
SANGER: Inhibition of human NCI-H716 cell growth in a cell viability assay.
SANGER: Inhibition of human NCI-H716 cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| NCI-H719 | IC50 |
78.264 μM
Compound: VX-680
|
SANGER: Inhibition of human NCI-H719 cell growth in a cell viability assay.
SANGER: Inhibition of human NCI-H719 cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| NCI-H720 | IC50 |
2.062 μM
Compound: VX-680
|
SANGER: Inhibition of human NCI-H720 cell growth in a cell viability assay.
SANGER: Inhibition of human NCI-H720 cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| NCI-H747 | IC50 |
3.942 μM
Compound: VX-680
|
SANGER: Inhibition of human NCI-H747 cell growth in a cell viability assay.
SANGER: Inhibition of human NCI-H747 cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| NCI-H748 | IC50 |
25.763 μM
Compound: VX-680
|
SANGER: Inhibition of human NCI-H748 cell growth in a cell viability assay.
SANGER: Inhibition of human NCI-H748 cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| NCI-H82 | IC50 |
2.838 μM
Compound: VX-680
|
SANGER: Inhibition of human NCI-H82 cell growth in a cell viability assay.
SANGER: Inhibition of human NCI-H82 cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| NCI-H889 | IC50 |
25.193 μM
Compound: VX-680
|
SANGER: Inhibition of human NCI-H889 cell growth in a cell viability assay.
SANGER: Inhibition of human NCI-H889 cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| NCI-N87 | IC50 |
11.6 μM
Compound: VX-680, MK-0457
|
Antiproliferative activity against human NCI-N87 cells assessed as cell viability after 72 hrs by CCK8 assay
Antiproliferative activity against human NCI-N87 cells assessed as cell viability after 72 hrs by CCK8 assay
|
[PMID: 24681066] |
| NEC8 | IC50 |
13.104 μM
Compound: VX-680
|
SANGER: Inhibition of human NEC8 cell growth in a cell viability assay.
SANGER: Inhibition of human NEC8 cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| NH-12 | IC50 |
403.265 μM
Compound: VX-680
|
SANGER: Inhibition of human NH-12 cell growth in a cell viability assay.
SANGER: Inhibition of human NH-12 cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| NKM-1 | IC50 |
1.028 μM
Compound: VX-680
|
SANGER: Inhibition of human NKM-1 cell growth in a cell viability assay.
SANGER: Inhibition of human NKM-1 cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| NMC-G1 | IC50 |
4.227 μM
Compound: VX-680
|
SANGER: Inhibition of human NMC-G1 cell growth in a cell viability assay.
SANGER: Inhibition of human NMC-G1 cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| no-10 | IC50 |
51.701 μM
Compound: VX-680
|
SANGER: Inhibition of human no-10 cell growth in a cell viability assay.
SANGER: Inhibition of human no-10 cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| no-11 | IC50 |
25.747 μM
Compound: VX-680
|
SANGER: Inhibition of human no-11 cell growth in a cell viability assay.
SANGER: Inhibition of human no-11 cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| NOMO-1 | IC50 |
3.023 μM
Compound: VX-680
|
SANGER: Inhibition of human NOMO-1 cell growth in a cell viability assay.
SANGER: Inhibition of human NOMO-1 cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| NOS-1 | IC50 |
3.848 μM
Compound: VX-680
|
SANGER: Inhibition of human NOS-1 cell growth in a cell viability assay.
SANGER: Inhibition of human NOS-1 cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| NTERA-2-cl-D1 | IC50 |
0.014 μM
Compound: VX-680
|
SANGER: Inhibition of human NTERA-S-cl-D1 cell growth in a cell viability assay.
SANGER: Inhibition of human NTERA-S-cl-D1 cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| OCI-AML2 | IC50 |
0.644 μM
Compound: VX-680
|
SANGER: Inhibition of human OCI-AML2 cell growth in a cell viability assay.
SANGER: Inhibition of human OCI-AML2 cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| OCUB-M | IC50 |
0.17 μM
Compound: VX-680
|
SANGER: Inhibition of human OCUB-M cell growth in a cell viability assay.
SANGER: Inhibition of human OCUB-M cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| OMC-1 | IC50 |
274.28 μM
Compound: VX-680
|
SANGER: Inhibition of human OMC-1 cell growth in a cell viability assay.
SANGER: Inhibition of human OMC-1 cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| ONS-76 | IC50 |
0.665 μM
Compound: VX-680
|
SANGER: Inhibition of human ONS-76 cell growth in a cell viability assay.
SANGER: Inhibition of human ONS-76 cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| OPM-2 | IC50 |
12.16 μM
Compound: VX-680
|
SANGER: Inhibition of human OPM-2 cell growth in a cell viability assay.
SANGER: Inhibition of human OPM-2 cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| OS-RC-2 | IC50 |
5.986 μM
Compound: VX-680
|
SANGER: Inhibition of human OS-RC-2 cell growth in a cell viability assay.
SANGER: Inhibition of human OS-RC-2 cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| OVCAR-4 | IC50 |
2.461 μM
Compound: VX-680
|
SANGER: Inhibition of human OVCAR-4 cell growth in a cell viability assay.
SANGER: Inhibition of human OVCAR-4 cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| P30-OHK | IC50 |
323.028 μM
Compound: VX-680
|
SANGER: Inhibition of human P30-OHK cell growth in a cell viability assay.
SANGER: Inhibition of human P30-OHK cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| P31-FUJ | IC50 |
481.069 μM
Compound: VX-680
|
SANGER: Inhibition of human P31-FUJ cell growth in a cell viability assay.
SANGER: Inhibition of human P31-FUJ cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| PANC-1 | IC50 |
4.13 μM
Compound: VX-680, MK-0457
|
Antiproliferative activity against human PANC1 cells assessed as cell viability after 72 hrs by CCK8 assay
Antiproliferative activity against human PANC1 cells assessed as cell viability after 72 hrs by CCK8 assay
|
[PMID: 24681066] |
| PC-3 | IC50 |
5.81 μM
Compound: VX-680, MK-0457
|
Antiproliferative activity against human PC3 cells assessed as cell viability after 72 hrs by CCK8 assay
Antiproliferative activity against human PC3 cells assessed as cell viability after 72 hrs by CCK8 assay
|
[PMID: 24681066] |
| PF-382 | IC50 |
3.358 μM
Compound: VX-680
|
SANGER: Inhibition of human PF-382 cell growth in a cell viability assay.
SANGER: Inhibition of human PF-382 cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| PSN1 | IC50 |
0.22 μM
Compound: VX-680
|
SANGER: Inhibition of human PSN1 cell growth in a cell viability assay.
SANGER: Inhibition of human PSN1 cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| QIMR-WIL | IC50 |
0.427 μM
Compound: VX-680
|
SANGER: Inhibition of human QIMR-WIL cell growth in a cell viability assay.
SANGER: Inhibition of human QIMR-WIL cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| Raji | IC50 |
30.559 μM
Compound: VX-680
|
SANGER: Inhibition of human Raji cell growth in a cell viability assay.
SANGER: Inhibition of human Raji cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| Ramos-2G6-4C10 | IC50 |
64.236 μM
Compound: VX-680
|
SANGER: Inhibition of human Ramos-2G6-4C10 cell growth in a cell viability assay.
SANGER: Inhibition of human Ramos-2G6-4C10 cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| RCC10RGB | IC50 |
92.94 μM
Compound: VX-680
|
SANGER: Inhibition of human RCC10RGB cell growth in a cell viability assay.
SANGER: Inhibition of human RCC10RGB cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| REH | IC50 |
25.467 μM
Compound: VX-680
|
SANGER: Inhibition of human REH cell growth in a cell viability assay.
SANGER: Inhibition of human REH cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| RH-1 | IC50 |
3.173 μM
Compound: VX-680
|
SANGER: Inhibition of human RH-1 cell growth in a cell viability assay.
SANGER: Inhibition of human RH-1 cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| RKO | IC50 |
0.308 μM
Compound: VX-680
|
SANGER: Inhibition of human RKO cell growth in a cell viability assay.
SANGER: Inhibition of human RKO cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| RL | IC50 |
448.463 μM
Compound: VX-680
|
SANGER: Inhibition of human RL cell growth in a cell viability assay.
SANGER: Inhibition of human RL cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| RL95-2 | IC50 |
0.406 μM
Compound: VX-680
|
SANGER: Inhibition of human RL95-2 cell growth in a cell viability assay.
SANGER: Inhibition of human RL95-2 cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| RPMI-6666 | IC50 |
2.162 μM
Compound: VX-680
|
SANGER: Inhibition of human RPMI-6666 cell growth in a cell viability assay.
SANGER: Inhibition of human RPMI-6666 cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| RPMI-8226 | IC50 |
71.624 μM
Compound: VX-680
|
SANGER: Inhibition of human RPMI-8226 cell growth in a cell viability assay.
SANGER: Inhibition of human RPMI-8226 cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| RPMI-8866 | IC50 |
468.649 μM
Compound: VX-680
|
SANGER: Inhibition of human RPMI-8866 cell growth in a cell viability assay.
SANGER: Inhibition of human RPMI-8866 cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| RS4-11 | IC50 |
0.004 μM
Compound: VX-680
|
SANGER: Inhibition of human RS4-11 cell growth in a cell viability assay.
SANGER: Inhibition of human RS4-11 cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| RXF 393 | IC50 |
32.497 μM
Compound: VX-680
|
SANGER: Inhibition of human RXF393 cell growth in a cell viability assay.
SANGER: Inhibition of human RXF393 cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| SBC-1 | IC50 |
1.125 μM
Compound: VX-680
|
SANGER: Inhibition of human SBC-1 cell growth in a cell viability assay.
SANGER: Inhibition of human SBC-1 cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| SCC-15 | IC50 |
366.065 μM
Compound: VX-680
|
SANGER: Inhibition of human SCC-15 cell growth in a cell viability assay.
SANGER: Inhibition of human SCC-15 cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| SCC-3 | IC50 |
77.581 μM
Compound: VX-680
|
SANGER: Inhibition of human SCC-3 cell growth in a cell viability assay.
SANGER: Inhibition of human SCC-3 cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| SCH | IC50 |
229.958 μM
Compound: VX-680
|
SANGER: Inhibition of human SCH cell growth in a cell viability assay.
SANGER: Inhibition of human SCH cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| SCLC-21H | IC50 |
1.971 μM
Compound: VX-680
|
SANGER: Inhibition of human SCLC-21H cell growth in a cell viability assay.
SANGER: Inhibition of human SCLC-21H cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| SF-126 | IC50 |
0.948 μM
Compound: VX-680
|
SANGER: Inhibition of human SF126 cell growth in a cell viability assay.
SANGER: Inhibition of human SF126 cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| SF-268 | IC50 |
4.799 μM
Compound: VX-680
|
SANGER: Inhibition of human SF268 cell growth in a cell viability assay.
SANGER: Inhibition of human SF268 cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| SF-539 | IC50 |
17.992 μM
Compound: VX-680
|
SANGER: Inhibition of human SF539 cell growth in a cell viability assay.
SANGER: Inhibition of human SF539 cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| Sf9 | IC50 |
0.023 μM
Compound: Tozasertib
|
Inhibition of GST-tagged AURORA A (unknown origin) expressed in baculovirus infected Sf9 cells using MBP as substrate
Inhibition of GST-tagged AURORA A (unknown origin) expressed in baculovirus infected Sf9 cells using MBP as substrate
|
[PMID: 30234987] |
| Sf9 | IC50 |
20 nM
Compound: 1, VX-680
|
Inhibition of GST-tagged Aurora kinase A catalytic domain (123 to 401 amino acids) (unknown origin) expressed in sf9 cells using tetra(LRRWSLG) as substrate preincubated for 15 mins prior to substrate addition measured after 90 mins by luminescence assay
Inhibition of GST-tagged Aurora kinase A catalytic domain (123 to 401 amino acids) (unknown origin) expressed in sf9 cells using tetra(LRRWSLG) as substrate preincubated for 15 mins prior to substrate addition measured after 90 mins by luminescence assay
|
[PMID: 23808327] |
| SH-4 | IC50 |
2.325 μM
Compound: VX-680
|
SANGER: Inhibition of human SH-4 cell growth in a cell viability assay.
SANGER: Inhibition of human SH-4 cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| SIG-M5 | IC50 |
0.167 μM
Compound: VX-680
|
SANGER: Inhibition of human SIG-M5 cell growth in a cell viability assay.
SANGER: Inhibition of human SIG-M5 cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| SIMA | IC50 |
526.427 μM
Compound: VX-680
|
SANGER: Inhibition of human SIMA cell growth in a cell viability assay.
SANGER: Inhibition of human SIMA cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| SJSA-1 | IC50 |
11.289 μM
Compound: VX-680
|
SANGER: Inhibition of human SJSA-1 cell growth in a cell viability assay.
SANGER: Inhibition of human SJSA-1 cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| SK-BR-3 | IC50 |
9.99 μM
Compound: VX-680, MK-0457
|
Antiproliferative activity against human SKBR3 cells assessed as cell viability after 72 hrs by CCK8 assay
Antiproliferative activity against human SKBR3 cells assessed as cell viability after 72 hrs by CCK8 assay
|
[PMID: 24681066] |
| SK-LMS-1 | IC50 |
1.222 μM
Compound: VX-680
|
SANGER: Inhibition of human SK-LMS-1 cell growth in a cell viability assay.
SANGER: Inhibition of human SK-LMS-1 cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| SKM-1 | IC50 |
53.069 μM
Compound: VX-680
|
SANGER: Inhibition of human SKM-1 cell growth in a cell viability assay.
SANGER: Inhibition of human SKM-1 cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| SK-MEL-1 | IC50 |
112.779 μM
Compound: VX-680
|
SANGER: Inhibition of human SK-MEL-1 cell growth in a cell viability assay.
SANGER: Inhibition of human SK-MEL-1 cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| SK-MEL-2 | IC50 |
245.248 μM
Compound: VX-680
|
SANGER: Inhibition of human SK-MEL-2 cell growth in a cell viability assay.
SANGER: Inhibition of human SK-MEL-2 cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| SK-MM-2 | IC50 |
19.555 μM
Compound: VX-680
|
SANGER: Inhibition of human SK-MM-2 cell growth in a cell viability assay.
SANGER: Inhibition of human SK-MM-2 cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| SK-N-DZ | IC50 |
0.962 μM
Compound: VX-680
|
SANGER: Inhibition of human SK-N-DZ cell growth in a cell viability assay.
SANGER: Inhibition of human SK-N-DZ cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| SK-NEP-1 | IC50 |
1.211 μM
Compound: VX-680
|
SANGER: Inhibition of human SK-NEP-1 cell growth in a cell viability assay.
SANGER: Inhibition of human SK-NEP-1 cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| SK-N-FI | IC50 |
2.869 μM
Compound: VX-680
|
SANGER: Inhibition of human SK-N-FI cell growth in a cell viability assay.
SANGER: Inhibition of human SK-N-FI cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| SK-PN-DW | IC50 |
0.791 μM
Compound: VX-680
|
SANGER: Inhibition of human SK-PN-DW cell growth in a cell viability assay.
SANGER: Inhibition of human SK-PN-DW cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| SK-UT-1 | IC50 |
0.16 μM
Compound: VX-680
|
SANGER: Inhibition of human SK-UT-1 cell growth in a cell viability assay.
SANGER: Inhibition of human SK-UT-1 cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| SNB-75 | IC50 |
10.076 μM
Compound: VX-680
|
SANGER: Inhibition of human SNB75 cell growth in a cell viability assay.
SANGER: Inhibition of human SNB75 cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| SNU1 | IC50 |
214.379 μM
Compound: VX-680
|
SANGER: Inhibition of human NCI-SNU-1 cell growth in a cell viability assay.
SANGER: Inhibition of human NCI-SNU-1 cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| SNU-16 | IC50 |
0.636 μM
Compound: VX-680
|
SANGER: Inhibition of human NCI-SNU-16 cell growth in a cell viability assay.
SANGER: Inhibition of human NCI-SNU-16 cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| SNU-5 | IC50 |
83.603 μM
Compound: VX-680
|
SANGER: Inhibition of human NCI-SNU-5 cell growth in a cell viability assay.
SANGER: Inhibition of human NCI-SNU-5 cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| SNU-C1 | IC50 |
28.943 μM
Compound: VX-680
|
SANGER: Inhibition of human SNU-C1 cell growth in a cell viability assay.
SANGER: Inhibition of human SNU-C1 cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| SNU-C2B | IC50 |
38.165 μM
Compound: VX-680
|
SANGER: Inhibition of human SNU-C2B cell growth in a cell viability assay.
SANGER: Inhibition of human SNU-C2B cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| SR | IC50 |
0.246 μM
Compound: VX-680
|
SANGER: Inhibition of human SR cell growth in a cell viability assay.
SANGER: Inhibition of human SR cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| ST486 | IC50 |
0.231 μM
Compound: VX-680
|
SANGER: Inhibition of human ST486 cell growth in a cell viability assay.
SANGER: Inhibition of human ST486 cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| SU-DHL-1 | IC50 |
231.383 μM
Compound: VX-680
|
SANGER: Inhibition of human SU-DHL-1 cell growth in a cell viability assay.
SANGER: Inhibition of human SU-DHL-1 cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| SUP-T1 | IC50 |
444.151 μM
Compound: VX-680
|
SANGER: Inhibition of human SUP-T1 cell growth in a cell viability assay.
SANGER: Inhibition of human SUP-T1 cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| SW 954 | IC50 |
0.122 μM
Compound: VX-680
|
SANGER: Inhibition of human SW954 cell growth in a cell viability assay.
SANGER: Inhibition of human SW954 cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| SW 962 | IC50 |
30.275 μM
Compound: VX-680
|
SANGER: Inhibition of human SW962 cell growth in a cell viability assay.
SANGER: Inhibition of human SW962 cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| SW684 | IC50 |
179.373 μM
Compound: VX-680
|
SANGER: Inhibition of human SW684 cell growth in a cell viability assay.
SANGER: Inhibition of human SW684 cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| SW872 | IC50 |
4.343 μM
Compound: VX-680
|
SANGER: Inhibition of human SW872 cell growth in a cell viability assay.
SANGER: Inhibition of human SW872 cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| SW982 | IC50 |
0.214 μM
Compound: VX-680
|
SANGER: Inhibition of human SW982 cell growth in a cell viability assay.
SANGER: Inhibition of human SW982 cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| TALL-1 | IC50 |
11.406 μM
Compound: VX-680
|
SANGER: Inhibition of human TALL-1 cell growth in a cell viability assay.
SANGER: Inhibition of human TALL-1 cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| TE-1 | IC50 |
5.49 μM
Compound: VX-680
|
SANGER: Inhibition of human TE-1 cell growth in a cell viability assay.
SANGER: Inhibition of human TE-1 cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| TE-10 | IC50 |
1.129 μM
Compound: VX-680
|
SANGER: Inhibition of human TE-10 cell growth in a cell viability assay.
SANGER: Inhibition of human TE-10 cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| TE-11 | IC50 |
0.15 μM
Compound: VX-680
|
SANGER: Inhibition of human TE-11 cell growth in a cell viability assay.
SANGER: Inhibition of human TE-11 cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| TE-12 | IC50 |
4.564 μM
Compound: VX-680
|
SANGER: Inhibition of human TE-12 cell growth in a cell viability assay.
SANGER: Inhibition of human TE-12 cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| TE-15 | IC50 |
0.851 μM
Compound: VX-680
|
SANGER: Inhibition of human TE-15 cell growth in a cell viability assay.
SANGER: Inhibition of human TE-15 cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| TE-441-T | IC50 |
34.637 μM
Compound: VX-680
|
SANGER: Inhibition of human TE-441-T cell growth in a cell viability assay.
SANGER: Inhibition of human TE-441-T cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| TE-5 | IC50 |
49.712 μM
Compound: VX-680
|
SANGER: Inhibition of human TE-5 cell growth in a cell viability assay.
SANGER: Inhibition of human TE-5 cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| TE-6 | IC50 |
48.446 μM
Compound: VX-680
|
SANGER: Inhibition of human TE-6 cell growth in a cell viability assay.
SANGER: Inhibition of human TE-6 cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| TE-8 | IC50 |
1.804 μM
Compound: VX-680
|
SANGER: Inhibition of human TE-8 cell growth in a cell viability assay.
SANGER: Inhibition of human TE-8 cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| TE-9 | IC50 |
3.267 μM
Compound: VX-680
|
SANGER: Inhibition of human TE-9 cell growth in a cell viability assay.
SANGER: Inhibition of human TE-9 cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| TGBC1TKB | IC50 |
27.558 μM
Compound: VX-680
|
SANGER: Inhibition of human TGBC1TKB cell growth in a cell viability assay.
SANGER: Inhibition of human TGBC1TKB cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| TGBC24TKB | IC50 |
0.864 μM
Compound: VX-680
|
SANGER: Inhibition of human TGBC24TKB cell growth in a cell viability assay.
SANGER: Inhibition of human TGBC24TKB cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| TGW | IC50 |
2.658 μM
Compound: VX-680
|
SANGER: Inhibition of human TGW cell growth in a cell viability assay.
SANGER: Inhibition of human TGW cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| THP-1 | IC50 |
510.276 μM
Compound: VX-680
|
SANGER: Inhibition of human THP-1 cell growth in a cell viability assay.
SANGER: Inhibition of human THP-1 cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| TK-10 | IC50 |
5.355 μM
Compound: VX-680
|
SANGER: Inhibition of human TK10 cell growth in a cell viability assay.
SANGER: Inhibition of human TK10 cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| TUR | IC50 |
431.377 μM
Compound: VX-680
|
SANGER: Inhibition of human TUR cell growth in a cell viability assay.
SANGER: Inhibition of human TUR cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| U-266 | IC50 |
28.637 μM
Compound: VX-680
|
SANGER: Inhibition of human U-266 cell growth in a cell viability assay.
SANGER: Inhibition of human U-266 cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| U-698-M | IC50 |
278.633 μM
Compound: VX-680
|
SANGER: Inhibition of human U-698-M cell growth in a cell viability assay.
SANGER: Inhibition of human U-698-M cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| U-87MG ATCC | IC50 |
14.5 μM
Compound: VX-680
|
Antiproliferative activity against human U87 cells assessed as cell growth inhibition after 72 hrs by MTT assay
Antiproliferative activity against human U87 cells assessed as cell growth inhibition after 72 hrs by MTT assay
|
[PMID: 32035750] |
| U-87MG ATCC | IC50 |
58.212 μM
Compound: VX-680
|
SANGER: Inhibition of human U-87-MG cell growth in a cell viability assay.
SANGER: Inhibition of human U-87-MG cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| U-937 | IC50 |
0.036 μM
Compound: VX-680
|
Antiproliferative activity against human U937 cells after 48 hrs by CCK8 assay
Antiproliferative activity against human U937 cells after 48 hrs by CCK8 assay
|
[PMID: 29358147] |
| U-937 | IC50 |
0.036 μM
Compound: VX-680, MK-0457
|
Antiproliferative activity against human U937 cells assessed as cell viability after 72 hrs by CCK8 assay
Antiproliferative activity against human U937 cells assessed as cell viability after 72 hrs by CCK8 assay
|
[PMID: 24681066] |
| UACC-257 | IC50 |
7.045 μM
Compound: VX-680
|
SANGER: Inhibition of human UACC-257 cell growth in a cell viability assay.
SANGER: Inhibition of human UACC-257 cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| VA-ES-BJ | IC50 |
0.201 μM
Compound: VX-680
|
SANGER: Inhibition of human VA-ES-BJ cell growth in a cell viability assay.
SANGER: Inhibition of human VA-ES-BJ cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| Vero C1008 | IC50 |
>2.0 × 105M
Compound: COVC-3361686327
|
Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging
Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging
|
10.6019/CHEMBL4651402 |
| WSU-NHL | IC50 |
511.692 μM
Compound: VX-680
|
SANGER: Inhibition of human WSU-NHL cell growth in a cell viability assay.
SANGER: Inhibition of human WSU-NHL cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
| YT | IC50 |
74.914 μM
Compound: VX-680
|
SANGER: Inhibition of human YT cell growth in a cell viability assay.
SANGER: Inhibition of human YT cell growth in a cell viability assay.
|
10.6019/CHEMBL1201861 |
Chemical Information
-
CAS No. 639089-54-6
-
분자량 464.59
-
화학식 C23H28N8OS
-
SMILES
O=C(C1CC1)NC2=CC=C(C=C2)SC3=NC(N4CCN(CC4)C)=CC(NC5=NNC(C)=C5)=N3
-
선적
Room temperature in continental US; may vary elsewhere.
-
보관
Please store the product under the recommended conditions in the Certificate of Analysis.
순도&문서
Select Batch:
Purity:
99.98%
Assay:
99.98%
ee.:
99.98%
References
Calculators
몰농도 계산기
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
=
×
×
농도 희석 계산기
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
DDR1-IN-11 Related Classifications
HY-173284 Related Classifications
Powered by Bioz